Flag of the European Union EU Clinical Trials Register Help

Clinical trials for RR interval

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    77 result(s) found for: RR interval. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2006-000182-10 Sponsor Protocol Number: CBI-GBM-01 Start Date*: 2006-05-04
    Sponsor Name:Rigshospitalet, Finsen Center
    Full Title: A phase II trial with cetuximab, bevacizumab and irinotecan for patients with malignant glioblastomas and progression after radiation therapy and temozolamid
    Medical condition: Recurrent or progressive primary GBM in patients with performance status (PS) 0-2.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2009-011819-20 Sponsor Protocol Number: V00067 CA 201 1A Start Date*: 2009-05-29
    Sponsor Name:Pierre Fabre Médicament
    Full Title: Effects of OMACOR in patients with a cardiac sodium channel gene SCN5A mutation, one variant of the congenital long-QT syndrome. A proof of concept study.
    Medical condition: Adult patients with a cardiac sodium channel gene SCN5A mutation, one variant of the congenital long-QT syndrome, with implantable cardioverter defibrillator (ICD).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057926 Long QT syndrome congenital LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2007-003323-20 Sponsor Protocol Number: CP4055-204 Start Date*: 2008-05-30
    Sponsor Name:Clavis Pharma ASA
    Full Title: A Phase I/II Study of CP-4055 in Patients with Platinum Resistant Ovarian Cancer
    Medical condition: A phase I/II clinical study of CP4055 in patients with platinum resistant ovarian cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-003783-27 Sponsor Protocol Number: PN06-CLD-01001 Start Date*: 2006-01-26
    Sponsor Name:PAION Deutschland GmbH
    Full Title: TOLERABILITY OF ENECADIN (INN) IN ACUTE ISCHEMIC STROKE TRIAL - TEST- PHASE IIA : A multicentre, double-blind, randomised, placebo-controlled, dose-escalating parallel- group study to investigate t...
    Medical condition: acute ischemic stoke Based on the results of preclinical studies, enecadin is expected to play an important role in the treatment of acute ischemic stroke and to ameliorate the outcome and prognos...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10061256 Ischaemic stroke PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BE (Completed) AT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-003283-10 Sponsor Protocol Number: BRAF01 Start Date*: 2020-11-11
    Sponsor Name:Camilla Qvortrup
    Full Title: BEACON regimen with cetuximab every second week - Cetuximab given every second week with encorafenib in pre-treated patients with BRAFV600E mutated metastatic colorectal cancer. A phase II study.
    Medical condition: Pre-treated BRAFV600E metastatic colorectal adenocarcinoma.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-001716-59 Sponsor Protocol Number: D4120C00002 Start Date*: 2011-10-14
    Sponsor Name:AstraZeneca AB
    Full Title: A Multi-Centre, Double-Blind, Randomised, Placebo-Controlled Phase II Study to Assess the Effects on Atrial and Ventricular Refractoriness of an Intravenous Infusion of AZD2927 in Patients Undergoi...
    Medical condition: Arrhythmia
    Disease: Version SOC Term Classification Code Term Level
    14.0 10007541 - Cardiac disorders 10003119 Arrhythmia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: View results
    EudraCT Number: 2015-004880-35 Sponsor Protocol Number: SUM111035 Start Date*: 2016-12-22
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Randomized, Multicenter, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Oral Sumatriptan for the Acute Treatment of Migraine in Children and Adolescents
    Medical condition: Migraine
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10027599 Migraine PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2022-001087-10 Sponsor Protocol Number: ELA-0121 Start Date*: 2022-11-21
    Sponsor Name:Stemline Therapeutics, Inc
    Full Title: An Open-label Multicenter Phase 1b-2 Study of Elacestrant as Monotherapy and in Combination with Abemaciclib in Women and Men with Brain Metastasis from Estrogen Receptor Positive, HER-2 Negative B...
    Medical condition: Brain Metastasis from Estrogen Receptor Positive, HER-2 Negative Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) IT (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-000206-18 Sponsor Protocol Number: PM1183-B-005-14-QT Start Date*: 2015-09-10
    Sponsor Name:PharmaMar S.A., Sociedad Unipersonal
    Full Title: Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization (QTc Duration) in Patients with Selected Solid Tumors
    Medical condition: - small cell lung cancer (SCLC) - head and neck carcinoma (H&N) - neuroendocrine tumors (NETs) - biliary tract carcinoma - endometrial carcinoma - BRCA 1/2-associated metastatic breast carcinoma - ...
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10048683 Advanced cancer LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-011044-20 Sponsor Protocol Number: D1710C00006 Start Date*: 2009-04-08
    Sponsor Name:AstraZeneca AB
    Full Title: A Single-Centre, Double-blind, Double-dummy, Randomised, Placebo Controlled, Four Period Crossover Study to Assess the Effect of Single Oral Doses of AZD5672 (600mg and 150mg) on QT/QTc Interval, C...
    Medical condition: rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039075 Rheumatoid arthritis and associated conditions HLT
    Population Age: Adults Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-000820-42 Sponsor Protocol Number: EFC10262 Start Date*: 2008-06-24
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: A Multinational, Randomized, Double-blind Study, Comparing the Efficacy of Aflibercept Once Every 2 Weeks versus Placebo in Patients with Metastatic Colorectal Cancer (MCRC) Treated with Irinotecan...
    Medical condition: Patients with metastatic colorectal cancer (MCRC) treated with irinotecan/5FU combination (FOLFIRI) after failure of an oxaliplatin based regimen.
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) GR (Completed) NL (Completed) CZ (Completed) EE (Completed) ES (Completed) DK (Completed) SE (Completed) BE (Completed) GB (Completed) IT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2007-003458-28 Sponsor Protocol Number: A00423 Start Date*: 2015-02-18
    Sponsor Name:UCB, Inc.
    Full Title: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study of the Safety of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 6 Months to 11 Months With...
    Medical condition: Allergic Rhinitis Chronic Urticaria
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004870 10001738 Allergy LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-000205-39 Sponsor Protocol Number: A00426 Start Date*: 2015-02-18
    Sponsor Name:UCB, Inc.
    Full Title: A Multi-Center, Randomized, Double Blind, Placebo Controlled Parallel Group Study of the Safety of Levocetirizine Dihydrochloride Oral Liquid Formulation b.i.d Dosing in Children Aged 1 to < 6 Year...
    Medical condition: Allergic Rhinitis Chronic Urticaria
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004870 10001738 Allergy LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-020343-13 Sponsor Protocol Number: ESTEVE-SIGM-106 Start Date*: 2010-06-21
    Sponsor Name:Laboratorios del Dr Esteve S.A
    Full Title: A double-blind, randomised, placebo-controlled, 4‑way cross-over Phase I study to investigate the pharmacokinetics, pharmacodynamics and safety of escalating single doses of E‑52862 in young health...
    Medical condition: Pain
    Disease: Version SOC Term Classification Code Term Level
    12.1 10033371 Pain LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-000819-29 Sponsor Protocol Number: EFC10261 Start Date*: 2007-09-26
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: A Multinational, Randomized, Double-Blind Study Comparing Aflibercept Versus Placebo in Patients Treated with Second-Line Docetaxel after Failure of One Platinum Based Therapy for Locally Advanced ...
    Medical condition: Patients treated with second-line docetaxel after failure of one platinum based therapy for locally advanced or metastatic non-small-cell lung cancer (NSCLC).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) GR (Completed) HU (Completed) IT (Completed) FR (Completed) AT (Prematurely Ended) EE (Completed) FI (Completed) SE (Completed) NL (Completed) BG (Completed) PT (Completed) GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-006011-74 Sponsor Protocol Number: BI-Brain-01 Start Date*: 2007-02-01
    Sponsor Name:Rigshospitalet
    Full Title: A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy
    Medical condition: Primary malignant brain tumors
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2011-001076-18 Sponsor Protocol Number: 26481585LYM2001 Start Date*: 2011-09-20
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 2, Single-arm, Open-label, Multicenter Study of the Histone Deacetylase Inhibitor (HDACi) JNJ-26481585 in Subjects With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma
    Medical condition: Stage Ib-IVa Cutaneous T-cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10011677 Cutaneous T-cell lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) ES (Completed) PT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-004698-29 Sponsor Protocol Number: TH-CR-415 Start Date*: 2014-05-12
    Sponsor Name:Threshold Pharmaceuticals, Inc.
    Full Title: A Randomized Phase 2, Double-blind, Placebo-controlled, Multi-center Study Comparing Pemetrexed in Combination with TH-302 vs. Pemetrexed in Combination with Placebo as Second-line Chemotherapy for...
    Medical condition: Advanced Non-Squamous, Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) IT (Completed) DE (Prematurely Ended) CZ (Completed) GR (Prematurely Ended) ES (Temporarily Halted) RO (Completed)
    Trial results: View results
    EudraCT Number: 2021-006331-26 Sponsor Protocol Number: UC-0107/1810 Start Date*: 2022-02-15
    Sponsor Name:UNICANCER
    Full Title: Phase 2, randomised trial testing the addition of upfront stereotactic radiosurgery to binimetinib, encorafenib plus pembrolizumab in comparison with binimetinib, encorafenib plus pembrolizumab alo...
    Medical condition: BRAF(V600) mutation-positive melanoma with brain metastasis (MBM)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-000043-32 Sponsor Protocol Number: NA Start Date*: 2014-03-21
    Sponsor Name:Fondazione IRCCS Istituto Nazionale dei Tumori
    Full Title: A Phase 2 study of Paclitaxel and Ifosfamide plus either Cisplatin or Carboplatin for patients with metastatic non-transitional cell carcinoma of the bladder and the urinary tract
    Medical condition: Non-transitional cell carcinoma of the bladder and the urinary tract
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10064467 Urothelial carcinoma LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 06 09:48:27 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA